Stock Ratings / Health Care / EVO / options

DRUG (46) STTK (31) NGNE (44) PBYI (71) ⌘ Pro Terminal →

Evotec SE (EVO) Options Positioning, Max Pain & Unusual Sweeps

$1.53 -3.16% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.52

Evotec SE (EVO) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $562.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EVO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Evotec SE (NASDAQ: EVO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $1.53 (-3.16% 1D, market cap $562.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, EVO ranks #343 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EVO compare to DRUG and STTK in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EVO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $556.7M) and STTK (Shattuck Labs Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $574.1M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EVO?

▼

For Evotec SE (EVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #343 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.52 (-0.76%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EVO)Realized 20D OHLCV Swing Band: ±7.3%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY EVO SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($15.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.37+3.6% Next Q

Q2 (-2Q)

Grade D$1.42+7% Next Q

Q3 (-1Q)

Grade D$1.52+0.7% Next Q

Current

Grade D$1.53-5.9% Hist 90D α

Trajectory: E (39) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EVO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EVO currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.64) and Max Pain ($1.61) forces dealer call-delta covering toward $4.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EVO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EVO Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±7.3%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (EVO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for EVO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EVO)

✓Walkthrough of EVO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.96%⚡ TESTING RESISTANCE

2026-11-02O $1.60H $1.60L $1.53C $1.53VOL 64.1K

RES: $1.58SUP: $1.17SMA50: $1.64SMA200: $2.51

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EVO Butterfly Map → + Track EVO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EVO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EVO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EVO)

Health Care Rank #343 of 1016 ⚔️ DRUG vs EVO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EVO vs. DRUG, STTK, NGNE, PBYI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Evotec SE (EVO) ranks #343 by composite RQD confidence (47/100, grade D) and #429 by equity capitalization ($562.1M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with EVO at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EVO ACTIVE Evotec SE	D	47/100	—	—	—	-3.16%	$562.1M	Benchmark Subject
DRUG Bright Minds Biosciences Inc.	D	46/100	—	—	—	-3.02%	$556.7M	/drug-vs-evo →
STTK Shattuck Labs Inc.	E	31/100	—	—	-35.0%	-2.80%	$574.1M	/sttk-vs-evo →
NGNE Neurogene Inc.	D	44/100	—	—	-35.0%	-4.41%	$576.7M	/ngne-vs-evo →
PBYI Puma Biotechnology Inc	B-	71/100	17.5x	74.5%	29.3%	-0.95%	$544.1M	/pbyi-vs-evo →

2. EVO Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Evotec SE (EVO) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $562.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. EVO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EVO compare to DRUG and STTK in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EVO?

Where is EVO trading relative to its 50-day, 200-day, and 52-week technical levels?

EVO last traded at $1.53 (-3.16% on volume of 73,257 shares), positioning the stock -6.71% below its 50-day simple moving average ($1.64) and -39.04% below its 200-day simple moving average ($2.51). Across its 52-week range of $1.33 to $4.09, EVO sits at the 7.2% percentile with a 14-day RSI of 51.4 (NEUTRAL RANGE) and an implied next-earnings move of ±7.3% ($1.42 to $1.64).

EVO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is EVO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for EVO.

Direct Sub-Reports: EVO RQD Cockpit EVO 12M Forecast EVO Earnings & Move EVO Dividends & DRIP EVO Insiders & 13F EVO Whale Options EVO Profit Sankey EVO News & Why

ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

EVO — Evotec SE: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:15:36Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 47 / D, labeled "Roarable Sell — Underperform / Distribution Warning" (per the Roarable RQD rating). The five pillars score as follows: Fundamental Cash Engine 12 of 20 (ROIC 0%; FCF yield 0%); Whale 13F Flow 5 of 20 (institutional accumulation and options positioning); Insider Conviction 9 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 8 of 20 (Beta 1.0; sector sensitivity); Forensic Balance Sheet 13 of 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are institutional flow and macro fit, with the cash engine also scoring low because the source reports ROIC and FCF yield at 0%. The balance-sheet pillar is the relative strength, with an Altman Z of 2.5 and a Piotroski F of 6/9 per the RQD rating. Upside drivers would need to come from a shift in the cash-generation picture, which the source data does not show. Valuation cannot be assessed on earnings multiples because P/E, Forward P/E, and EV/EBITDA are not available in source data. The stock's 52-week range of $1.33 - $4.09 and current price of 1.58 place it in the lower portion of that range (per market data), which the rating interprets as distribution rather than accumulation.

Business

Evotec SE (EVO) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile identifies a market capitalization of $0.6B. Product, customer, and revenue-model details are not available in source data.

Recent Catalysts & News Wire Analysis

The most prominent item is a headline reporting that Evotec appointed Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, flagged as a YELLOW light in the news wire. Other wire items are flagged as YELLOW (Yahoo! Finance Canada and ad-hoc-news.de headlines) or GREEN (a Siam report stating the ADR slipped 0.64% to $1.55 near the lower end of its range, and a report of a 9.51 percent weekly gain as results near). Several wire summaries are generic templates and contain no substantive fundamental content. The wire-flagged risk watch item is the ADR trading near the lower end of its range, per the Siam headline. Proprietary signals in the Butterfly Supply-Chain Graph are empty.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

The Butterfly Supply-Chain Graph reports supply_chain as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data.

Open Questions

What are reported revenue, operating income, net income, EPS, free cash flow, cash, and debt for any period, given that the financials section is empty?
What are the current valuation multiples (P/E, Forward P/E, EV/EBITDA), since these are absent from the source data?
What is the analyst consensus rating and price target distribution?
Who are the institutional (13F) and insider (Form 4) holders, and what is their recent net activity?
What is the company's pipeline and commercial revenue base that would drive the cash-generation pillar higher?

EVO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Evotec SE (EVO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EVO Debate Forum (3) ↓

🟡 MARKET WIRE Investing News Network • 15h ago

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

Investing News Network report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 18h ago

Alvotech (ALVO) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 21h ago

Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday

Benzinga report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Evotec SE (EVO) Slips 0.64% to $1.55 as ADR Holds Near Lower End of Range - Revenue Growth Stocks

https://www.siam.in/ report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Evotec stock trades at EUR 2.61 with EUR 0.5 billion market value

ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ad-hoc-news.de • 1d ago

Evotec stock gains 9.51 percent over the week as results near

ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Evotec stock at EUR 2.56 ahead of the Xetra open: drug discovery group slightly lower

ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Berenberg keeps EUR 3.60 target for Evotec stock

ad-hoc-news.de report covering Evotec SE (EVO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EVO Bull vs. Bear Conversation Board — What's Your Call at $1.53?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EVO 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.71 (+8.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is EVO (D • RQD 47/100) a Buy at $1.58?

Welcome to the EVO (Evotec SE) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.26 (-20.3%)

Spot @ $1.58

Pump the brakes on EVO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EVO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Evotec SE expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.02 (+27.8%)

Spot @ $1.58

EVO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EVO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.58 (52-wk range $1.33 - $4.09), any beat on forward guidance forces shorts and underweight funds to chase.